

## Announcement Regarding Revision of Business Forecasts

Sysmex Corporation has revised its business forecast released on May 9, 2012. This revision is based on the recent business environment.

1. Revised Consolidated Business Forecast

(April 1, 2012 to March 31, 2013)

(unit: million yen)					
	Net Sales	Operating income	Ordinary income	Net income	Net income per share (yen)
Previous forecast (A)	148,000	21,000	21,000	13,000	126.45
Revised forecast (B)	140,000	20,000	19,500	12,100	117.59
Change (B – A)	(8,000)	(1,000)	(1,500)	(900)	-
Rate of Change (%)	(5.4)	(4.8)	(7.1)	(6.9)	-
Result of previous year					
	134,743	19,205	19,130	12,007	116.85

2. Reasons for the Revision

For the fiscal year ending March 31, 2013, we now expect net sales to fall below our previously forecast figures, owing to such factors as the delayed introduction into the U.S. market (due to extended approval procedures) of our new top-end model in the hematology field, the XN-Series of multiparameter automated hematology analyzers, as well as concern about Chinese market deceleration. On the profit front, although we are working to reduce cost of sales and curtail selling, general and administrative expenses, we estimate that operating income will undershoot our previous forecast. Furthermore, because of a worsening non-operating balance stemming from foreign exchange losses, we expect ordinary income to be below our previously forecast figure. We have revised our forecast for the full fiscal year accordingly.

For the third quarter onward, we maintain the initial exchange rate assumptions at US1.00 =¥80 and €1.00 =¥105.

Note: The forecasts above were made based on information available on the day of this release. Actual results may therefore differ materially from those described above due to various unforeseen factors and possible events in the future.